EirGenix - Asset Resilience Ratio
EirGenix (6589) has an Asset Resilience Ratio of 4.60% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EirGenix PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how EirGenix's Asset Resilience Ratio has changed over time. See how leveraged is EirGenix's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down EirGenix's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EirGenix stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$500.00 Million | 4.6% |
| Total Liquid Assets | NT$500.00 Million | 4.60% |
Asset Resilience Insights
- Limited Liquidity: EirGenix maintains only 4.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EirGenix Industry Peers by Asset Resilience Ratio
Compare EirGenix's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for EirGenix (2017–2024)
The table below shows the annual Asset Resilience Ratio data for EirGenix.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.60% | NT$500.00 Million ≈ $15.75 Million |
NT$10.88 Billion ≈ $342.67 Million |
+0.12pp |
| 2023-12-31 | 4.48% | NT$500.00 Million ≈ $15.75 Million |
NT$11.16 Billion ≈ $351.68 Million |
-3.96pp |
| 2022-12-31 | 8.44% | NT$1.00 Billion ≈ $31.51 Million |
NT$11.85 Billion ≈ $373.25 Million |
-6.11pp |
| 2021-12-31 | 14.55% | NT$1.66 Billion ≈ $52.45 Million |
NT$11.44 Billion ≈ $360.45 Million |
+11.57pp |
| 2020-12-31 | 2.99% | NT$114.52 Million ≈ $3.61 Million |
NT$3.84 Billion ≈ $120.83 Million |
-6.67pp |
| 2017-12-31 | 9.65% | NT$163.64 Million ≈ $5.16 Million |
NT$1.70 Billion ≈ $53.41 Million |
-- |
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more